PRMT5阻害剤は,肺アデノカルシノーマの転移進行を積極的に促進する
bioRxiv : the preprint server for biology
|February 12, 2026
まとめ
タンパク質アルギニンメチルトランスフェラーゼ5阻害剤 (PRMT5i) は,逆説的に,肺腺癌の攻撃的ながんの進行と抵抗を加速させることができます. この薬物誘発の可塑性は,臨床応用に関して懸念を喚起しています.
科学分野:
- 腫瘍学 腫瘍学
- エピジェネティクス エピジェネティクス
- がん生物学 がん生物学
背景:
- エピジェネティック変異は,がんの進行の主要な原動力である.
- タンパク質アルギニンメチルトランスフェラーゼ5 (PRMT5) は,臨床試験における阻害剤 (PRMT5i) が標的とする表遺伝子調節剤である.
- PRMT5阻害剤に対する耐性のメカニズムは,依然としてほとんど不明です.
研究 の 目的:
- 肺腺がん (LUAD) のPRMT5阻害剤耐性のメカニズムと結果を調査する.
- PRMT5の阻害ががんの進行や耐性獲得に影響するかどうかを判断する.
主な方法:
- 独立したPRMT5阻害剤耐性LUAD細胞系を生成する.
- 肺腫瘍を患ったマウスを用いたin vivo研究.
- クロマチン再配線分析. クロマチンの再配線分析.
- 人間の細胞系と患者コホートの分析.
主要な成果:
- PRMT5阻害剤に対する耐性の獲得は,積極的ながんの進行と分化シグネチャにつながる.
- 耐性細胞は,体内では転移の可能性が増加している.
- PRMT5の阻害は,クロマチンの急速な再配線を誘発し,病後期の状態の抑制を可能にします.
- In vivoでは,PRMT5の阻害は,腫瘍の負担を軽減することなく,急速な疾患進行を促進します.
- 人間の細胞系と患者コホートから得られたデータは,PRMT5の抑制媒介による脱差を裏付けている.
結論:
- PRMT5阻害剤は,様々な腫瘍タイプにおける自己抵抗性および疾患進行を積極的に促進することができます.
- 薬剤による可塑性,耐性,および疾患進行は,PRMT5阻害剤を含む臨床試験において考慮されるべきである.
関連する概念動画
01:52Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
02:40The Eukaryotic Promoter Region
19.0K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
19.0K
02:40The Eukaryotic Promoter Region
4.0K
4.0K
01:47Lung Capacity
56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
02:07Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
00:50Anaphase Promoting Complex
3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K